Dropulic B - Search Results

1

Current status of gene therapy strategies to treat HIV/AIDS.

Strayer DS, Akkina R, Bunnell BA, Dropulic B, Planelles V, Pomerantz RJ, Rossi JJ, Zaia JA. Strayer DS, et al. Among authors: dropulic b. Mol Ther. 2005 Jun;11(6):823-42. doi: 10.1016/j.ymthe.2005.01.020. Mol Ther. 2005. PMID: 15922953 Free article. Review.

2

Gene therapy for human immunodeficiency virus infection: genetic antiviral strategies and targets for intervention.

Dropulić B, Jeang KT. Dropulić B, et al. Hum Gene Ther. 1994 Aug;5(8):927-39. doi: 10.1089/hum.1994.5.8-927. Hum Gene Ther. 1994. PMID: 7948142 Review.

3

Ribozymes: use as anti-HIV therapeutic molecules.

Dropulic B, Elkins DA, Rossi JJ, Sarver N. Dropulic B, et al. Antisense Res Dev. 1993 Spring;3(1):87-94. doi: 10.1089/ard.1993.3.87. Antisense Res Dev. 1993. PMID: 8495108 No abstract available.

4

Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load.

Humeau LM, Binder GK, Lu X, Slepushkin V, Merling R, Echeagaray P, Pereira M, Slepushkina T, Barnett S, Dropulic LK, Carroll R, Levine BL, June CH, Dropulic B. Humeau LM, et al. Among authors: dropulic b, dropulic lk. Mol Ther. 2004 Jun;9(6):902-13. doi: 10.1016/j.ymthe.2004.03.005. Mol Ther. 2004. PMID: 15194057 Free article.

5

Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance.

Lu X, Yu Q, Binder GK, Chen Z, Slepushkina T, Rossi J, Dropulic B. Lu X, et al. Among authors: dropulic b. J Virol. 2004 Jul;78(13):7079-88. doi: 10.1128/JVI.78.13.7079-7088.2004. J Virol. 2004. PMID: 15194784 Free PMC article.

6

Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome.

Dropulic B, June CH. Dropulic B, et al. Hum Gene Ther. 2006 Jun;17(6):577-88. doi: 10.1089/hum.2006.17.577. Hum Gene Ther. 2006. PMID: 16776567 Review.

7

Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection.

Kimpel J, Braun SE, Qiu G, Wong FE, Conolle M, Schmitz JE, Brendel C, Humeau LM, Dropulic B, Rossi JJ, Berger A, von Laer D, Johnson RP. Kimpel J, et al. Among authors: dropulic b. PLoS One. 2010 Aug 23;5(8):e12357. doi: 10.1371/journal.pone.0012357. PLoS One. 2010. PMID: 20808813 Free PMC article.

8

Stable Transcriptional Repression and Parasitism of HIV-1.

Shrivastava S, Charlins P, Ackley A, Embree H, Dropulic B, Akkina R, Weinberg MS, Morris KV. Shrivastava S, et al. Among authors: dropulic b. Mol Ther Nucleic Acids. 2018 Sep 7;12:12-18. doi: 10.1016/j.omtn.2018.04.011. Epub 2018 May 1. Mol Ther Nucleic Acids. 2018. PMID: 30195752 Free PMC article.

9

Lentivirus in the clinic.

Dropulic B. Dropulic B. Mol Ther. 2001 Dec;4(6):511-2. doi: 10.1006/mthe.2001.0501. Mol Ther. 2001. PMID: 11735332 Free article. No abstract available.

10

In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication.

Davis BM, Humeau L, Dropulic B. Davis BM, et al. Among authors: dropulic b. Mol Ther. 2004 Feb;9(2):160-72. doi: 10.1016/j.ymthe.2003.11.003. Mol Ther. 2004. PMID: 14759800 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

68 results

Search Page